HOST - DAPT Duration According the Bleeding Risk

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 4900 participants.

Also called NCT05631769

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 4,900 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05631769
Other papers using this trial's data
  • Dual antiplatelet therapy after percutaneous coronary intervention according to bleeding risk (HOST-BR): an open-label, multicentre, randomised clinical trial Lancet (London, England), 2025-11-08 DOI, PubMed 41631724

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT05631769. Randomized; single masking; primary purpose treatment. Start 2020-07-24 (actual); primary completion 2024-12-31 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
HOST - DAPT Duration According the Bleeding Risk
Acronym
HOST-BR
Condition
Acute Myocardial Infarction
Condition
Stable Angina
Intervention (Drug)
Dual antiplatelet agent duration
Lead sponsor
Seoul National University Hospital (class: other)
Collaborator
Hanyang University Seoul Hospital (class: other)

Record details

Record id
cardio:ct-nct05631769
Content hash
82b378989c204bafe73a20dda5b4e152cecdf49470139f6508f33b8afcf5e92a